BiotechSwings
First ADC out of the gate for $AVBP and it did not whisper
ARR 217 in GI cancers, 44.8 percent response at 6 mg per kg in late line colorectal patients, 123 treated, generally well tolerated
premarket popped about 9 percent and now it moves into Phase 1b dose optimization with 2027 data next
1
